KMT2A and leukemia: Past work has suggested that MLL-AF4 leukemias are particularly sensitive to loss of BCL-2 activity [20], and we were able to extend this observation by illustrating that BCL-2 is a key therapeutic target in MLL-AF4 leukemias [18].